Contents
Working directories
1 | # HPV30 |
1 | setsid /usr/bin/google-chrome-stable %U https://hotliu.github.io/ |
Reading
1 | i=/media/ht/ht_5T/Work/References/Important_Journals/Not_Classified |
Margin Note/Import
1 | setsid firefox http://192.168.1.7:8000/ |
Vaccine-related publications
1 | i=/media/ht/ht_5T/Work/Projects/Other_Projects/Coronavirus_Project/Ref/Vaccine/20210114 |
Vaccines
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine - PubMed
- Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial - PubMed
- Immunological considerations for COVID-19 vaccine strategies - PubMed
- Prospects for a safe COVID-19 vaccine - PubMed
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates - PubMed
- COVID-19 Vaccine: A comprehensive status report - PubMed
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet
- Use of adenovirus type-5 vectored vaccines: a cautionary tale - The Lancet
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates - PubMed
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults - PubMed
1 | i=/media/ht/ht_5T/Work/Projects/Other_Projects/Coronavirus_Project/Ref/Vaccine/20210114 |
- COVID-19_Vaccine-A_comprehensive_status_report.epub
- COVID-19_Vaccine-A_comprehensive_status_report.pdf
- Immunological_considerations_for_COVID-19_vaccine_strategies.pdf
- Prospects_for_a_safe_COVID-19_vaccine.pdf
- Safety_and_Efficacy_of_the_BNT162b2_mRNA_Covid-19_Vaccine.pdf
- Safety_and_Immunogenicity_of_SARS-CoV-2_mRNA-1273_Vaccine_in_Older_Adults.pdf
- Safety_and_Immunogenicity_of_Two_RNA-Based_Covid-19_Vaccine_Candidates.pdf
- Safety_tolerability_and_immunogenicity_of_a_recombinant_adenovirus_type-5_vectored_COVID-19_vaccine-a_dose-escalation_open-label_non-randomised_first-in-human_trial_cn.pdf
- Safety_tolerability_and_immunogenicity_of_a_recombinant_adenovirus_type-5_vectored_COVID-19_vaccine-a_dose-escalation_open-label_non-randomised_first-in-human_trial.pdf
- Safety_tolerability_and_immunogenicity_of_a_recombinant_adenovirus_type-5_vectored_COVID-19_vaccine-a_dose-escalation_open-label_non-randomised_first-in-human_trial_Supp.pdf
- Sinovac-PROFISCOV.pdf
- Sinovac-PROFISCOV_Supp.pdf
- Use_of_adenovirus_type-5_vectored_vaccines-a_cautionary_tale.pdf